Table 1 Baseline characteristics of the study population. ECOG Eastern Cooperative Oncology Group.
Characteristic | LRRT, n (%) | Without-LRRT, n (%) | P |
|---|---|---|---|
Age (year) | 1.000 | ||
< 50 | 35 (50.7) | 11 (52.4) | |
≥ 50 | 34 (49.3) | 10 (47.6) | |
Gender | 1.000 | ||
Male | 56 (81.2) | 17 (81.0) | |
Female | 13 (18.8) | 4 (19.0) | |
ECOG score | 0.233 | ||
0 | 0 (0) | 1 (4.8) | |
1 | 69 (100) | 20 (95.2) | |
T stage | 0.771 | ||
T1-2 | 17 (24.6) | 4 (19.0) | |
T3-4 | 52 (75.4) | 17 (81.0) | |
N stage | 0.506 | ||
N0-1 | 12 (17.4) | 2 (9.5) | |
N2-3 | 57 (82.6) | 19 (90.5) | |
Pre-treatment EBV DNA | 0.121 | ||
< 66,600 | 47 (68.1) | 10 (47.6) | |
≥ 66,600 | 22 (31.9) | 11 (52.4) | |
Multiple organ metastasis | 0.012 | ||
No | 42 (60.9) | 6 (28.6) | |
Yes | 27 (39.1) | 15 (71.4) | |
No. of metastatic lesions | 0.177 | ||
Single | 14 (20.3) | 1 (4.8) | |
Multiple | 55 (79.7) | 20 (95.2) | |
Liver metastases | 0.006 | ||
No | 47 (68.1) | 7 (33.3) | |
Yes | 22 (31.9) | 14 (66.7) | |
Bone metastases | 0.430 | ||
No | 24 (34.8) | 5 (23.8) | |
Yes | 45 (65.2) | 16 (76.2) | |
Lung metastases | 0.792 | ||
No | 47 (68.1) | 13 (61.9) | |
Yes | 22 (31.9) | 8 (38.1) | |
Lactate dehydrogenase (U/L) | 0.036 | ||
< 250 | 44 (67.7) | 8 (40.0) | |
≥ 250 | 21 (32.3) | 12 (60.0) | |
Cycle of first-line chemotherapy | 0.202 | ||
< 6 | 24 (34.8) | 11 (52.4) | |
≥ 6 | 45 (65.2) | 10 (47.6) | |
Cycle of first-line immune therapy | 0.040 | ||
< 8 | 37 (53.6) | 17 (81.0) | |
≥ 8 | 32 (46.4) | 4 (19.0) | |
Local treatment to metastasis | 0.005 | ||
No | 44 (63.8) | 20 (95.2) | |
Yes | 25 (36.2) | 1 (4.8) | |
